Alternative management of persistent Hyperinsulinemic hypoglycemia in a neonate: A case report on octreotide and nifedipine therapy
Abstract
This case report highlights the successful management of Persistent Hyperinsulinemic Hypoglycemia in Infancy (PHHI) using alternative therapies, demonstrating their efficacy and practical implications in resource-limited settings. A 48-hour-old neonate presented with severe hypoglycemia unresponsive to high-dose glucose infusion. Laboratory investigations confirmed PHHI with elevated insulin and C-peptide levels. Due to the unavailability of diazoxide, treatment involved subcutaneous octreotide and oral nifedipine. The clinical course was managed and monitored according to international guidelines for hyperinsulinemic hypoglycemia. The combination therapy successfully stabilized blood glucose levels, enabling cessation of intravenous glucose infusion by day 10. The patient also recovered fully from hospital-acquired pneumonia with antibiotic treatment. These outcomes underscore the potential efficacy of nifedipine as a viable second-line therapy for PHHI in contexts where standard treatments are inaccessible. This case underscores the importance of flexible, evidence-based therapeutic approaches tailored to individual patient needs, especially in resource-constrained environments. The findings highlight nifedipine’s clinical utility in PHHI management and emphasize the need for further research, including large-scale studies, to establish standardized treatment protocols and expand access to effective therapies globally.
How strong is the evidence?
Evidence Hub reads this as a case report, done in people. Its evidence level is 5 of 5 (Very low · case / narrative / animal / in vitro / in silico). Case reports, narrative reviews, and animal, cell or computer-model studies give the weakest evidence for human health.
Read the paper
Related studies
- Penicillins for Treatment of Pneumococcal Pneumonia: Does In Vitro Resistance Really Matter?
- Thiophenes—Naturally Occurring Plant Metabolites: Biological Activities and In Silico Evaluation of Their Potential as Cathepsin D Inhibitors
- Inhalable Mannosylated Rifampicin–Curcumin Co-Loaded Nanomicelles with Enhanced In Vitro Antimicrobial Efficacy for an Optimized Pulmonary Tuberculosis Therapy
- Development and validation of microbial bioassay for quantification of Levofloxacin in pharmaceutical preparations
- GC-MS Analysis and Biomedical Therapy of Oil from n-Hexane Fraction of Scutellaria edelbergii Rech. f.: In Vitro, In Vivo, and In Silico Approach
- Propranolol, chlorpromazine and diclofenac restore susceptibility of extensively drug-resistant (XDR)-Acinetobacter baumannii to fluoroquinolones
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.